The FDA has noticeably shifted its approach to drug approval, releasing new recommendations that give drug developers a wider array of outcome measures to prove the efficacy of new medication-assisted treatments for opioid use disorder.
FDA gives drugmakers new ways to prove opioid disorder treatments work
